Article

Alternative strategies successful in managing IFIS

Las Vegas-Ophthalmologists can use one of several modified strategies to perform cataract surgery in patients who are taking or have taken tamsulosin (Flomax, Boehringer Ingelheim Pharmaceuticals), with good outcomes and low complication rates, when they know of the medication history in advance, David F. Chang, MD, told those attending the annual meeting of the American Academy of Ophthalmology here.

Combining different approaches also can be effective, he said. Stopping the drug is of questionable value, and pupil-stretching should be avoided, he added.

"We wanted the surgeons to be able to choose whatever strategy or combination they felt would be safest for their patients, so this was not a randomized comparison of different techniques in an attempt to see which was superior," Dr. Chang said.

Chosen strategies

Surgeons tended to use hooks and rings in patients with smaller preoperative pupil diameters (mean of 5.8 mm and 4.3 mm, respectively), which usually are indicative of more severe IFIS, Dr. Chang said.

Thirty-five percent of all of the cases involved dense nuclei, he said. Seventy-five percent of the procedures were performed using topical anesthesia. "Most [91%] were done using a phaco chop method, which indicates that these were very experienced surgeons," Dr. Chang added.

Nothing unusual was noted about the distribution of iris color, diabetes, or pseudoexfoliation in the patient population.

Results

Atropine as a single strategy was effective in only 42% (eight of 19) of the cases for which it was chosen, Dr. Chang said. In these cases, preoperative pupil diameter was very large (mean 7.2 mm) and decreased only slightly (mean 0.9 mm) by the end of the procedure. A well-dilated pupil at the start of surgery may indicate that the IFIS is less severe, he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
© 2025 MJH Life Sciences

All rights reserved.